You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: ELIMU INFORMATICS INC Topic: 172
PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: TDA RESEARCH, INC. Topic: 102
Project Summary AbstractDevelopment of a Nerve Cuff Electrode from Soft and Elastomeric Conducting Wires STTR Phase I ApplicationPIBrady ClapsaddleTDA ResearchIncBio electronic interfaces are used in a wide array of applications for recording and providing electrical impulses to treat diseaseOne common interface device for the PNS is the cuff electrodeCurrent cuff electrodes have many failure mode ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Marblehead Medical LLC Topic: 106
PROJECT SUMMARY ABSTRACTThis research program s broadlong term objective is to improve health outcomes for patients suffering fromacute ischemic strokeAISresulting from large vessel occlusionsWe will achieve this purpose by developingimproved access tools for stroke intervention procedureswhich specifically target tool innovations that providesupport for embolectomy devices and arrest flow during ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: INNOVAREGI LLC Topic: 400
AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOMIMETIX JV LLC Topic: 102
Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: NCI
DESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDS
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: INVENUX, LLC Topic: NCCAM
DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: BioTime, Inc. Topic: 100
ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Vova Ida, LLC Topic: 999
SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health